GBIM Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (14 Mär 2024 @ 19:43):

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform...

Stats
Tagesvolumen	756.00
Durchschnittsvolumen	0.00
Marktkapitalisierung	10 065.00
EPS	$-0.150 ( 2016-05-12 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2016-03-16	Mitchell Daniel J	Sell	8 862	Common Stock
2016-03-17	Mitchell Daniel J	Sell	12 468	Common Stock
2016-03-16	Mitchell Daniel J	Sell	112	Common Stock
2016-03-17	Mitchell Daniel J	Sell	158	Common Stock
2016-03-11	Mitchell Daniel J	Sell	76 662	Common Stock

INSIDER POWER
0.00
Last 99 transactions
Buy: 1 518 952 \| Sell: 29 605 418

Volumen Korrelation

Lang: -0.32 (neutral)

Kurz: 0.21 (neutral)

Signal:(24.043) Neutral

GlobeImmune, Inc. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

GlobeImmune, Inc. Korrelation - Währung/Rohstoff

0.00
( neutral )

GlobeImmune, Inc. Finanzdaten

Annual	2022
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$0

FY	2022
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$0

FY	2015
Umsatz:	$6.46M
Bruttogewinn:	$6.46M (100.00 %)
EPS:	$-0.480

FY	2014
Umsatz:	$5.97M
Bruttogewinn:	$5.97M (100.00 %)
EPS:	$-5.58

Financial Reports:

No articles found.

GlobeImmune, Inc.

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.